1.
Cui C, Ott PA, Wu CJ. Advances in Vaccines for Melanoma. Hematology/oncology clinics of North America. 2024. doi:10.1016/j.hoc.2024.05.009.
1.
Conway JR, Gillani R, Crowdis J, et al. Somatic structural variants drive distinct modes of oncogenesis in melanoma. The Journal of clinical investigation. 2024;134(13). doi:10.1172/JCI177270.
1.
Conway JR, Gillani R, Crowdis J, et al. Somatic structural variants drive distinct modes of oncogenesis in melanoma. The Journal of clinical investigation. 2024;134(13). doi:10.1172/JCI177270.
1.
Conway JR, Gillani R, Crowdis J, et al. Somatic structural variants drive distinct modes of oncogenesis in melanoma. The Journal of clinical investigation. 2024;134(13). doi:10.1172/JCI177270.
1.
Conway JR, Gillani R, Crowdis J, et al. Somatic structural variants drive distinct modes of oncogenesis in melanoma. The Journal of clinical investigation. 2024;134(13). doi:10.1172/JCI177270.
1.
Foda BM, Misek SA, Gallo KA, Neubig RR. Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade. International journal of cancer. 2024. doi:10.1002/ijc.35056.
1.
Wohlfarth J, Kosnopfel C, Faber D, et al. Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density. Molecular oncology. 2024. doi:10.1002/1878-0261.13660.
1.
Wohlfarth J, Kosnopfel C, Faber D, et al. Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density. Molecular oncology. 2024. doi:10.1002/1878-0261.13660.
1.
Funchain P, Ni Y, Heald B, et al. Germline Cancer Susceptibility in Individuals with Melanoma. Journal of the American Academy of Dermatology. 2024. doi:10.1016/j.jaad.2023.11.070.
1.
Dedeilia A, Lwin T, Li S, et al. Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma. Annals of surgical oncology. 2023. doi:10.1245/s10434-023-14724-5.